This should be trading much closer to book value. Pipeline seems overvalued. The share price should better reflect the risky and long-term nature of drug development.
Expect it to settle around the $1 mark, and then trade sideways from there. The Evogenix merger will probably cut 20 to 30% off the combined entity, as I believe the premium paid was excessive.
PTD
unknown
heading lower
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)